Get started
Author

Narayanan Nair Srihari

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
2015 · Nicholas D James, Matthew R Sydes, et al. · The Lancet · 2,055
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
2017 · Nicholas D. James, Johann S. de Bono, et al. · New England Journal of Medicine · 1,859
PDF
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
2018 · Christopher C Parker, Nicholas D James, et al. · The Lancet · 1,312
PDF
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
2019 · N.W. Clarke, A. Ali, et al. · Annals of Oncology · 410
PDF
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
2018 · M.R. Sydes, M.R. Spears, et al. · Annals of Oncology · 256
PDF
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial
2015 · Nicholas D. James, Melissa R. Spears, et al. · JAMA Oncology · 200
PDF
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
2022 · Chris C. Parker, Nicholas D. James, et al. · PLoS Medicine · 138
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
2023 · Gerhardt Attard, Laura Murphy, et al. · The Lancet Oncology · 134
PDF
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
2012 · Nicholas D James, Matthew R Sydes, et al. · The Lancet Oncology · 125
PDF
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
2023 · Janet E Brown, Kara-Louise Royle, et al. · The Lancet Oncology · 92
PDF
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
2022 · Nicholas D. James, Noel W. Clarke, et al. · International Journal of Cancer · 84
PDF
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
2017 · Malcolm D. Mason, Noel W. Clarke, et al. · Journal of Clinical Oncology · 73
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial
2024 · Chris C Parker, Noel W Clarke, et al. · The Lancet · 58
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
2025 · Silke Gillessen, Laura Murphy, et al. · The Lancet Oncology · 35
PDF
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial
2023 · Nalinie Joharatnam-Hogan, Duaa Hatem, et al. · British Journal of Cancer · 34
PDF
Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)
2018 · Christopher M. Nutting, James P. Morden, et al. · European Journal of Cancer · 34
PDF
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)
2019 · Manuela Schmidinger, Aristotelis Bamias, et al. · The Oncologist · 32
PDF
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
2018 · Beth S. Woods, Eleftherios Sideris, et al. · European Urology Oncology · 27
PDF
Impaired postoperative neutrophil leucocytosis and acute complications following short course preoperative radiotherapy for operable rectal cancer
2003 · A Hartley, S Giridharan, et al. · European Journal of Surgical Oncology · 23
Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma
2019 · Giuseppe Procopio, Aristotelis Bamias, et al. · Clinical Genitourinary Cancer · 16
LBA70 Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE
2024 · S. Gillessen, L.R. Murphy, et al. · Annals of Oncology · 10
PDF
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial
2025 · Gianmarco Leone, Francesco Orlando, et al. · JAMA Oncology · 9
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
2020 · N.W. Clarke, A. Ali, et al. · Annals of Oncology · 8
PDF
Patients’ Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study
2024 · Martin J. Connor, Mesfin Genie, et al. · European Urology Oncology · 5
Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations
2026 · Sara Elena Rebuzzi, Aruni Ghose, et al. · The Oncologist · 4
Works count: 33
Citation count: 7,044
H-index: 19
I10-index: 21
Year
Topic
Type